Synthesis of novel sulfide-based cyclic peptidomimetic analogues to solonamides

• José Brango-Vanegas,
• Luan A. Martinho,
• Lucinda J. Bessa,
• Andreanne G. Vasconcelos,
• Alexandra Plácido,
• Alex L. Pereira,
• José R. S. A. Leite and
• Angelo H. L. Machado

Beilstein J. Org. Chem. 2019, 15, 2544–2551, doi:10.3762/bjoc.15.247

• reported for solonamides. Keywords: antivirulence drug; bacteria; macrocyclization; pathoblocker; quorum quenching; Introduction The cyclodepsipeptides called solonamides A and B are natural molecules extracted from the marine bacterium Photobacterium halotolerans [1][2] (Figure 1). They are able to

Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections

• Matthew B. Calvert,
• Varsha R. Jumde and
• Alexander Titz

Beilstein J. Org. Chem. 2018, 14, 2607–2617, doi:10.3762/bjoc.14.239

• market with an antivirulence drug. The monoclonal antibody bezlotoxumab binds to C. difficile toxin B and was approved for the prevention of infections with this intestinal pathogen in 2016 [52]. Obiltoxaximab [53] and raxibacumab [54] are two approved antibody treatments for inhalative anthrax that